KLRC1 and cancer: Similarly, increased NKG2A expression in tumor-infiltrated immune effector cells was also reported in many human cancers (Sun et al., 2017, van Montfoort et al., 2018, Abd Hamid et al., 2019), suggesting that αNKG2A-N215 treatment might also predominantly induce intratumoral immune responses.